Clinical Trials Browser

Phase 1 × Neoplasms, Plasma Cell × Panobinostat × Clear all

NCT00532389 2020-12-19

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00532675 2020-12-19

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01440582 2019-03-04

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00962507 2013-02-15

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Phase 1 Completed

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell